Abstract
Purpose
The purpose of this study is to assess sexual function among patients with clinically localized prostate cancer referred for radiotherapy and to prospectively evaluate the effect of radiotherapy on sexual function, using the Brief Sexual Function Inventory (BSFI).
Materials and methods
A descriptive study, approved by the local research ethics committee, was prospectively conducted. At baseline, patients were asked to complete a self-administered BSFI, along with other questionnaires describing their clinical condition. Patients with normal erection at baseline were asked to complete a follow-up BSFI at 6, 12, and 24 months postradiotherapy. The collected data was analyzed using the SAS software.
Results
The study accrued a total of 117 eligible patients. The mean age was 66 years. Forty-two patients (35.9%) were considered to have erectile dysfunction (ED) at baseline. They were older and more likely on one or more medications affecting potency, compared with those with normal erectile function. They had a consistently lower mean score for all the five domains of BSFI and considered sexual activity less important. Of the 75 patients reporting normal erectile function at baseline, 61 completed a follow-up BSFI questionnaire. Among the 61 patients, 52 underwent radiotherapy with external beam radiotherapy or brachytherapy. Mean scores for all the BSFI domains declined after radiotherapy, suggesting that radiotherapy adversely affected not only erectile function but also other aspects of sexual function including sexual drive and ejaculation.
Conclusion
Among the patients with clinically localized prostate cancer referred for radiotherapy, sexual dysfunction was prevalent with 35.9% reporting ED at presentation. Radiotherapy adversely affected all aspects of sexual function.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anonymous (1993) NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 270:83–90. doi:10.1001/jama.270.1.83
Jonler M, Moon T, Brannan W et al (1995) The effect of age, ethnicity and geographical location on impotence and quality of life. Br J Urol 75:651–655. doi:10.1111/j.1464-410X.1995.tb07426.x
Feldman HA, Goldstein I, Hatzichristou DG et al (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151:54–61
Canadian Cancer Society. Available at http://cancer.ca/?sc_lang=en. Accessed December 2008
Singer PA, Tasch ES, Stocking C et al (1991) Sex or survival: trade-offs between quality and quantity of life. J Clin Oncol 9:328–334
Incrocci L, Slob AK, Levendag PC (2002) Sexual (dys) function after radiotherapy for prostate cancer: a review. Int J Radiat Oncol Biol Phys 52:681–693. doi:10.1016/S0360-3016(01)02727-4
O’Leary MP, Fowler FJ, Lenderking WR et al (1995) A brief male sexual function inventory for urology. Urology 46:697–706. doi:10.1016/S0090-4295(99)80304-5
Valicenti RK, Choi E, Chen C et al (2001) Sildenafil citrate effectively reverses sexual dysfunction induced by three-dimensional conformal radiation therapy. Urology 57:769–773. doi:10.1016/S0090-4295(00)01104-3
Chen CT, Valicenti RK, Lu J et al (2001) Does hormonal therapy influence sexual function in men receiving 3D conformal radiation therapy for prostate cancer? Int J Radiat Oncol Biol Phys 50:591–599. doi:10.1016/S0360-3016(01)01504-8
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Choo, R., Long, J., Gray, R. et al. Prospective survey of sexual function among patients with clinically localized prostate cancer referred for definitive radiotherapy and the impact of radiotherapy on sexual function. Support Care Cancer 18, 715–722 (2010). https://doi.org/10.1007/s00520-009-0675-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-009-0675-6